Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
Administration, Intravenous
Animals
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Neutralizing
/ administration & dosage
Antibodies, Viral
/ administration & dosage
Callithrix
Coronavirus Infections
/ prevention & control
Disease Models, Animal
Humans
Lung
/ drug effects
Middle East Respiratory Syndrome Coronavirus
Common marmoset
LCA60
MERS-CoV
Neutralizing monoclonal antibody
Prophylaxis
Treatment
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
21
01
2019
accepted:
23
01
2019
pubmed:
27
1
2019
medline:
14
3
2020
entrez:
27
1
2019
Statut:
ppublish
Résumé
Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.
Identifiants
pubmed: 30684561
pii: S0166-3542(19)30036-1
doi: 10.1016/j.antiviral.2019.01.016
pmc: PMC7113761
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-74Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Antiviral Res. 2017 Jul;143:30-37
pubmed: 28389142
Nat Med. 2013 Oct;19(10):1313-7
pubmed: 24013700
Euro Surveill. 2012 Sep 27;17(39):
pubmed: 23041020
J Infect Dis. 2017 Jun 15;215(12):1807-1815
pubmed: 28472421
PLoS Pathog. 2014 Aug 21;10(8):e1004250
pubmed: 25144235
Euro Surveill. 2012 Oct 04;17(40):20290
pubmed: 23078800
Antiviral Res. 2016 Aug;132:141-8
pubmed: 27312105
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603
pubmed: 24062443
Vet Pathol. 2016 May;53(3):521-31
pubmed: 26869154
Cell Res. 2015 Nov;25(11):1237-49
pubmed: 26391698
Sci Rep. 2016 Aug 19;6:31629
pubmed: 27538452
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8
pubmed: 26216974
J Infect Public Health. 2016 May-Jun;9(3):231-5
pubmed: 27102927
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43
pubmed: 26124093
Virology. 2016 Mar;490:49-58
pubmed: 26828465
Nature. 2013 Sep 19;501(7467):439-43
pubmed: 23955151
J Virol. 2018 Aug 29;92(18):
pubmed: 29950421
Antiviral Res. 2018 Aug;156:64-71
pubmed: 29885377